J
Jessica Perazzelli
Researcher at Children's Hospital of Philadelphia
Publications - 14
Citations - 1799
Jessica Perazzelli is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 7, co-authored 11 publications receiving 1327 citations. Previous affiliations of Jessica Perazzelli include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo,David M. Barrett,Kathryn L. Black,Asen Bagashev,Derek A. Oldridge,Glendon S. Wu,Robyn T. Sussman,Claudia Lanauze,Marco Ruella,Matthew R. Gazzara,Nicole M. Martinez,Colleen T. Harrington,Elaine Y. Chung,Jessica Perazzelli,Ted J. Hofmann,Shannon L. Maude,Pichai Raman,Alejandro Barrera,Saar Gill,Simon F. Lacey,J. Joseph Melenhorst,David Allman,Elad Jacoby,Terry J. Fry,Crystal L. Mackall,Yoseph Barash,Kristen W. Lynch,John M. Maris,Stephan A. Grupp,Andrei Thomas-Tikhonenko +29 more
TL;DR: It is discovered that the underlying mechanism is the selection for preexisting alternatively spliced CD19 isoforms with the compromised CART-19 epitope, which suggests a possibility of targeting alternative CD19 ectodomains, which could improve survival of patients with B-cell neoplasms.
Journal ArticleDOI
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella,David M. Barrett,Saad S. Kenderian,Olga Shestova,Ted J. Hofmann,Jessica Perazzelli,Michael Klichinsky,Vania Aikawa,Farzana Nazimuddin,Miroslaw Kozlowski,John Scholler,Simon F. Lacey,J. Joseph Melenhorst,Jennifer J.D. Morrissette,David A. Christian,Christopher A. Hunter,Michael Kalos,Michael Kalos,David L. Porter,Carl H. June,Stephan A. Grupp,Saar Gill +21 more
TL;DR: It is found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration, indicating that targeting CD19 and CD123 on leukemic blasts represents an effective strategy for treating and preventing antigen-loss relapses occurring after CD19
Journal ArticleDOI
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.
TL;DR: It is reported that T cell populations enriched for early lineage cells expanded better in vitro, and enrichment of this population either by timing of T cell collection or culture method can increase the number of patients eligible to receive highly active engineered cellular therapies.
Journal ArticleDOI
Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response
Jessica B. Foster,Namrata Choudhari,Jessica Perazzelli,Julie Storm,Ted J. Hofmann,Payal Jain,Phillip B. Storm,Norbert Pardi,Drew Weissman,Angela J. Waanders,Stephan A. Grupp,Katalin Karikó,Adam C. Resnick,David M. Barrett +13 more
TL;DR: In vivo studies using a leukemia mouse model revealed that the most robust 100-fold suppression of leukemic burden was achieved using T cells electroporated with purified mRNAs, regardless of their nucleoside modification.
Journal ArticleDOI
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
Nathan Singh,Noelle V. Frey,Boris Engels,David M. Barrett,Olga Shestova,Pranali Ravikumar,Katherine D. Cummins,Yong Gu Lee,Raymone Pajarillo,Inkook Chun,Amy Shyu,Steven Highfill,Andrew Price,Linlin Zhao,Liaomin Peng,Brian Granda,Melissa Ramones,Xueqing Maggie Lu,David A. Christian,Jessica Perazzelli,Simon F. Lacey,Nathan H. Roy,Janis K. Burkhardt,Florent Colomb,Mohammad Damra,Mohamed Abdel-Mohsen,Ting Liu,Dongfang Liu,Daron M. Standley,Regina M. Young,Jennifer Brogdon,Stephan A. Grupp,Carl H. June,Shannon L. Maude,Saar Gill,Marco Ruella +35 more
TL;DR: In this article, the authors present the composite outcomes of two pilot clinical trials ( NCT02588456 and NCT02650414 ) of T cells bearing a 4-1BB-based, CD22-targeting CAR in patients with relapsed or refractory ALL.